World's Best Scientists 2026 revealed!
Richard G. Langley

Richard G. Langley

D-Index & Metrics

Medicine

D-Index
83
Citations
32165
World Ranking
15434
National Ranking
644

Richard G. Langley publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Richard G. Langley sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 284 publications — 14th percentile

14% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Richard G. Langley D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Richard G. Langley sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 83 D-Index — 24th percentile

24% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Richard G. Langley is affiliated with Dalhousie University in Canada. Their research primarily focuses on medicine, immunology, and microbiology, with significant contributions in immunology, dermatology, pathology and forensic medicine, pediatrics, perinatology and child health, and physiology.

The scientist's work covers a range of topics within dermatology and immune-related diseases. Major areas of study include psoriasis treatment and pathogenesis, dermatology and skin diseases, autoimmune bullous skin diseases, pharmaceutical studies and practices, asthma and respiratory diseases, health systems, economic evaluations, quality of life, and urticaria and related conditions.

Frequent publication venues for Richard G. Langley include the Journal of the American Academy of Dermatology, SKIN The Journal of Cutaneous Medicine, British Journal of Dermatology, Dermatology and Therapy, and JAMA Dermatology.

Co-authors who have collaborated multiple times with Langley are Mark Lebwohl, Andrew Blauvelt, Richard B. Warren, Kristian Reich, and Bruce Strober.

Some recent notable papers published by or involving Richard G. Langley are:

  • Bimekizumab versus Secukinumab in Plaque Psoriasis, 2021, New England Journal of Medicine
  • Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial, 2021, The Lancet
  • Bimekizumab versus Adalimumab in Plaque Psoriasis, 2021, New England Journal of Medicine
  • Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis, 2020, JAMA Dermatology
  • A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial, 2020, British Journal of Dermatology

Best Publications

  • Secukinumab in plaque psoriasis--results of two phase 3 trials.

    Richard G. Langley;Boni E. Elewski;Mark Lebwohl;Kristian Reich

  • Psoriasis: epidemiology, clinical features, and quality of life

    R G B Langley;G G Krueger;C E M Griffiths

  • A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.

    Gerald G. Krueger;Richard G. Langley;Craig Leonardi;Newman Yeilding

  • Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

    Alan Menter;Stephen K. Tyring;Kenneth Gordon;Alexa B. Kimball

  • Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

    Mark Lebwohl;Bruce Strober;Alan Menter;Kenneth Gordon

  • Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).

    Jean-Hilaire Saurat;G. Stingl;L. Dubertret;K. Papp

  • Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

    Kenneth B Gordon;Jean-Frederic Colombel;Dana S Hardin

  • Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment

    Richard G. Langley;Charles N. Ellis

  • Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study

    Kenneth B. Gordon;Richard G. Langley;Craig Leonardi;Darryl Toth

  • Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

    Kim Papp;Kristian Reich;Craig L. Leonardi;Leon Kircik

  • Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey

    Mark G. Lebwohl;Hervé Bachelez;Jonathan Barker;Giampiero Girolomoni

  • Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study

    K.A. Papp;R.G. Langley;B. Sigurgeirsson;M. Abe

  • Etanercept treatment for children and adolescents with plaque psoriasis.

    Amy S. Paller;Elaine C. Siegfried;Richard G. Langley;Alice B. Gottlieb

  • An International, Randomized, Double-blind, Placebo-Controlled Phase 3 Trial of Intramuscular Alefacept in Patients With Chronic Plaque Psoriasis

    Mark Lebwohl;Enno Christophers;Richard Langley;Jean P. Ortonne

  • Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents.

    Lawrence F. Eichenfield;Anne W. Lucky;Mark Boguniewiczc;Richard G.B. Langley

  • A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis†

    K.A. Papp;K. Reich;C. Paul;A. Blauvelt

  • Long-term Safety and Efficacy of 50 mg of Etanercept Twice Weekly in Patients With Psoriasis

    Stephen Tyring;Kenneth B. Gordon;Yves Poulin;Richard G. Langley

  • Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part I, efficacy

    Jon M. Hanifin;Mark R. Ling;Richard Langley;Debra Breneman

  • Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.

    K.A. Papp;A. Menter;B. Strober;R.G. Langley

  • Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Results from two randomized, placebo-controlled, phase III trials

    K.A. Papp;M.A. Menter;M. Abe;B. Elewski

Frequent Co-Authors

Kim Papp
Kim Papp Probity Medical Research
Mark Lebwohl
Mark Lebwohl Icahn School of Medicine at Mount Sinai
Kenneth B. Gordon
Kenneth B. Gordon Medical College of Wisconsin
Kristian Reich
Kristian Reich University of Göttingen
Alice B. Gottlieb
Alice B. Gottlieb Icahn School of Medicine at Mount Sinai
Andrew Blauvelt
Andrew Blauvelt Veterans Health Administration
Carle Paul
Carle Paul Federal University of Toulouse Midi-Pyrénées
Craig L. Leonardi
Craig L. Leonardi Saint Louis University
Christopher E.M. Griffiths
Christopher E.M. Griffiths University of Manchester
Alan Menter
Alan Menter Texas A&M University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

As interest grows in studying Medicine in the USA, many students are also considering related online degrees and alternative career pathways in healthcare. The flexibility of online programs can make advanced qualifications more accessible than ever, especially for those with busy schedules or work commitments.

For nurses seeking to elevate their careers, the fastest dnp online program options provide a way to quickly achieve a Doctor of Nursing Practice. Those looking for more manageable admission requirements or workloads can explore dnp online programs designed with efficiency and support in mind.

If you’re beginning your healthcare journey, a lpn program can be completed online and lead directly into practical nursing roles in a relatively short period. For those interested in mental health, some of the shortest online pmhnp programs offer a fast-track route to becoming a Psychiatric Mental Health Nurse Practitioner.

These programs combine convenience with rigorous training, making them ideal options for anyone wishing to advance or pivot their healthcare career without committing to traditional, on-campus education.

Best Scientists Citing Richard G. Langley

Trending Scientists

Recently Published Articles